Liver Cancer
- Colon, Esophagus, Liver, PancreasAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid TumorsPrincipal Investigator: Michael Cecchini
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Francine Foss
- Pediatrics, Other Skin, Small Intestine, Soft Tissue, Ovary, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Urinary, Other Male Genital, Other Respiratory and Intrathoracic Organs, Brain and Nervous System, Bones and Joints, Hodgkin's Lymphoma, Kidney, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Liver, Lymphoid Leukemia, Eye and Orbit, Leukemia, otherThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyPrincipal Investigator: Farzana Pashankar